Workflow
Exscientia plc(EXAI)
icon
Search documents
Exscientia (EXAI) Earnings Call Presentation
2025-07-04 11:32
Transaction Overview - Recursion and Exscientia are combining to bring better medicines to patients more rapidly and cost efficiently[11] - Exscientia shareholders will receive 0.7729 shares of Recursion Class A common stock for each Exscientia ordinary share[27] - Recursion shareholders will own approximately 74% of the combined company, while Exscientia shareholders will own approximately 26%[27] - The transaction is expected to close by early 2025, subject to shareholder approvals and closing conditions[27] Financial Synergies and Cash Position - The combined company will have approximately $850 million in cash as of the end of Q2 2024[11, 27] - Estimated annual synergies of $100 million or more are expected[11, 27] - The pro forma combined financial plans are expected to extend the cash runway into 2027[27] Pipeline and Partnerships - The combined company anticipates approximately 10 clinical readouts over the next 18 months[11, 12, 14] - Current partnerships have the potential for over $200 million in milestone payments over the next 2 years[11, 18] - The combined company has the potential for over $20 billion in total revenue before royalties from partners[18] - CDK4/6 inhibitors generated $11 billion in sales in 2023[31]
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
GlobeNewswire News Room· 2024-11-20 12:00
Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find novel insights and dramatically reduce the time and cost of discovery Recursion will host an update call today, November 20, 2024 at 7:30 a.m. ET / 5:30 a.m. MT / 12:30 p.m. GMT on LinkedIn, X and Youtube SALT LAKE ...
Recursion and Exscientia Shareholders Approve the Proposed Combination
GlobeNewswire News Room· 2024-11-13 14:08
Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and Exscientia. The transaction is expected to close on November 20, 2024, subject to the satisfaction or waiver of the remaining customary closing conditions. Recursion expects to host an update call after the anticipated close on November 20, 2024 at 7:30 a.m. ET / 5:30 a.m ...
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
GlobeNewswire News Room· 2024-10-30 12:22
Salt Lake City, UT, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its Q3 2024 financial results on Wednesday, Nov 6, 2024, following the close of the financial markets. The company will not host its normal L(earnings) Call in relation to the business updates and financials for the third quarter. Instead, the company expects to host an update cal ...
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
The Motley Fool· 2024-08-11 08:59
Core Viewpoint - The merger between Exscientia and Recursion Pharmaceuticals aims to create a leading AI-driven drug discovery company, despite challenges in clinical evidence supporting AI's effectiveness in drug development [1][2]. Company Overview - Recursion Pharmaceuticals is set to become the largest AI-fueled drug discovery business following its merger with Exscientia, which has raised concerns about its current clinical progress and financial health [3][4]. - The combined entity will leverage different methodologies: Recursion focuses on large-scale experiments and data mining, while Exscientia utilizes published data and patient samples for drug candidate discovery [4][5]. Clinical Development - Following the merger, Recursion anticipates reporting results from 10 clinical trials over the next 18 months, with the potential for some candidates to become approved drugs if AI-driven discovery proves effective [6]. - The company has established partnerships with major pharmaceutical firms such as Sanofi, Bayer, Merck KGaA, and Roche, with potential milestone payments exceeding $20 billion, excluding royalties [7]. Financial Position - Recursion Pharmaceuticals has a market capitalization of approximately $1.6 billion, which is considered high for a clinical-stage drugmaker that has not yet entered phase 3 trials [8]. - As of June 30, 2024, Recursion has accumulated a deficit of $1.2 billion, raising concerns about its financial sustainability given its lack of advanced drug candidates [11]. Industry Challenges - The value proposition of Recursion's technology is questioned by big pharma, as improvements are primarily focused on the early stages of drug development, which may not justify the high costs associated with later stages [9]. - Despite its promise to expedite drug development, Recursion has not yet initiated any phase 3 trials, indicating a slower-than-expected progress in bringing new drug candidates to market [10].
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
Benzinga· 2024-08-08 21:37
On Thursday, Exscientia plc EXAI agreed to merge with Recursion Pharmaceuticals Inc. RXRX. Exscientia shareholders will receive 0.7729 Recursion shares for each Exscientia share, with fractional shares paid in cash. Based on the fixed exchange ratio, Recursion shareholders will own approximately 74% of the combined entity, and Exscientia shareholders will own approximately 26%. Also Read: Recursion Pharmaceuticals Stock Surges 10% As Nvidia-Powered Supercomputer Completion Sparks Investor Optimism. "We beli ...
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
Newsfilter· 2024-08-08 11:39
● Brings together Recursion's scaled biology exploration and translational capabilities with Exscientia's precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platform . Combined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methods · Highly complementar ...
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
GlobeNewswire News Room· 2024-08-08 11:39
● Brings together Recursion's scaled biology exploration and translational capabilities with Exscientia's precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platform . Combined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methods · Highly complementar ...
EXAI LAWSUIT ALERT: The Gross Law Firm Notifies Exscientia plc Investors of a Class Action Lawsuit and Upcoming Deadline
Prnewswire· 2024-06-25 09:45
NEW YORK, June 25, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI). CLASS PERIOD: March 23, 2022 to February 12, 2024 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of EXAI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is June 25, 2024. There ...
EXAI Today Is The Last Day that Investors can Lead Exscientia plc Fraud Lawsuit
Prnewswire· 2024-06-25 08:00
Group 1 - A class action lawsuit has been filed against Exscientia plc for violations of the Securities Exchange Act of 1934 and related rules [1] - The class period for the lawsuit is from September 13, 2022, to October 9, 2023, during which investors are encouraged to contact the law firm if they suffered losses [2] - The lawsuit alleges that Exscientia made false and misleading statements, with former CEO Andrew Hopkins engaging in improper relationships and former Chairman David Nicholson having knowledge of these issues [6] Group 2 - The company is accused of failing to maintain its Code of Business Conduct and Ethics, which left it vulnerable to improper conduct [6] - The public statements made by Exscientia were deemed false and materially misleading throughout the class period, leading to investor damages when the truth was revealed [6] - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [7]